Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanguo, has submitted a drug registration application for a new drug targeting ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients, which has been accepted by the National Medical Products Administration [1] Group 1 - The new drug is an innovative small molecule chemical drug [1] - The application is specifically for the treatment of patients with ALK-positive locally advanced or metastatic NSCLC [1] - Another indication for the drug, targeting ROS1-positive non-small cell lung cancer, has completed Phase II clinical trials in mainland China [1]

Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Fosun Wanguo, has submitted a drug registration application for a new drug, SAF-189, aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [1] - The new drug is an innovative small molecule chemical drug, with another indication for ROS1-positive NSCLC having completed Phase II clinical trials in mainland China as of the announcement date [1] - As of November 2025, the cumulative R&D investment for this new drug is approximately RMB 480 million (unaudited) [1] Group 2 - According to IQVIA CHPA data, the sales revenue for major drugs treating ALK-positive NSCLC in mainland China is projected to be approximately RMB 3.367 billion in 2024 [1]

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanbang, has submitted a drug registration application for a new indication of a drug targeting ALK-positive non-small cell lung cancer, which has been accepted by the National Medical Products Administration [1] Group 1 - Fosun Pharma announced that its subsidiary Fosun Wanbang has received acceptance for a drug registration application for Dihydroartemisinin-Ruxolitinib capsules [1] - The application is specifically for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK) [1]

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanbang, has submitted a drug registration application for a new drug, SAF-189, which targets ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients [1] Group 1 - The drug SAF-189 is classified as a Class 1 chemical drug [1] - The application has been accepted by the National Medical Products Administration of China [1] - The indication for the new drug is specifically for patients with ALK-positive locally advanced or metastatic NSCLC [1]

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanbang, has submitted a drug registration application for SAF-189, a new drug aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [1] Group 1 - The drug registration application has been accepted by the National Medical Products Administration [1] - SAF-189 is classified as a Class 1 chemical drug [1] - The indication for this new drug is specifically for patients with ALK-positive NSCLC [1]

Core Viewpoint - Fosun Pharma has submitted a drug registration application for SAF-189, a drug for treating ALK-positive locally advanced or metastatic non-small cell lung cancer, which has been accepted by the National Medical Products Administration [1] Group 1 - Fosun Pharma's subsidiary, Fosun Wanguo (Jiangsu) Pharmaceutical Group Co., Ltd., is responsible for the drug registration application [1] - The application is classified as a Class 1 chemical drug [1] - The indication for the drug is specifically for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer [1]

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanbang, has submitted a drug registration application for a new drug, SAF-189, which targets ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients, and the application has been accepted by the National Medical Products Administration [1] Group 1 - The new drug, SAF-189, is classified as a Class 1 chemical drug and is an innovative small molecule chemical drug [1] - In addition to the current application, another indication for SAF-189, targeting ROS1-positive non-small cell lung cancer, has completed Phase II clinical trials in mainland China as of January 8, 2026 [1]

Policy Developments - Guizhou Province is advancing the monitoring of adverse reactions to medical institution formulations, highlighting issues such as insufficient awareness and inadequate responsibility among institutions [1] - Liaoning Province is implementing a tiered management system for outpatient medical insurance settlements at designated medical institutions starting next year, aiming to improve the efficiency of medical insurance fund usage [2] Drug and Device Approvals - GlaxoSmithKline announced that the NMPA has approved the use of its Shingrix vaccine for adults aged 18 and older with known diseases or treatments that increase the risk of shingles, addressing a significant health concern in China with approximately 6 million cases annually [2] - Shanghai Pharmaceuticals received FDA approval for its doxycycline capsules, primarily used for treating inflammatory lesions of rosacea, with projected sales of approximately $130 million in the U.S. for 2024 [3] - Gilead Sciences has completed pre-NDA communication with the NMPA regarding its new drug denifanstat for treating moderate to severe acne, planning to submit the application soon [4] - BD Medical's PleurX IPC system has been approved for clinical use in mainland China under the "Hong Kong and Macau Drug and Device Pass" policy [5] Capital Market Activities - Shanghai Guotou signed agreements with 10 general partners during the 2025 Shanghai International Biopharmaceutical Week, marking a significant step in building a comprehensive fund matrix for the biopharmaceutical industry [6][7] - Jinhai Biological announced plans to issue shares through a simplified procedure, which was approved by its board and supervisory board [8] Industry Events - Guangdong Province's Drug Inspection Institute has launched a new experimental zone for batch release, enhancing the province's capacity for vaccine quality assurance [9] Public Sentiment Alerts - Fosun Pharma announced the withdrawal of its registration application for dimethyl succinate for the treatment of non-small cell lung cancer, stating that this will not significantly impact current performance as they plan to improve the registration materials and resubmit [10]

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanguo (Jiangsu) Pharmaceutical Group, has received notification from the National Medical Products Administration regarding the withdrawal of its registration application for Dihydroartemisinin-Ruxolitinib capsules [2] Group 1 - The announcement was made on the evening of October 14 [2] - The withdrawal of the registration application indicates a strategic decision by the company [2]

Core Viewpoint - Fosun Pharma (02196) announced that its subsidiary, Fosun Wanguo (Jiangsu) Pharmaceutical Group Co., Ltd., has received notification from the National Medical Products Administration (NMPA) regarding the withdrawal of the registration application for the drug Dihydrosuccinimide Ruxolitinib Capsules (project code: SAF-189) [1] Group 1 - The drug is an innovative small molecule chemical drug primarily intended for the treatment of non-small cell lung cancer (ALK+) and non-small cell lung cancer (ROS1+) [1] - The registration application for this drug for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) positivity was accepted by the NMPA in March 2025 [1] - The withdrawal of the registration application does not signify the termination of the project; Fosun Wanguo will enhance the registration materials according to the latest technical requirements from the NMPA and will resubmit the application as soon as possible [1] Group 2 - The withdrawal of the registration application is not expected to have a significant impact on the current performance of the group (including the company and its subsidiaries) [1]